Essential guide to the Psychedelic Renaissance: All you need to know about how psilocybin, MDMA and LSD are revolutionizing mental health and changing lives

Antón Gómez-Escolar

May 2022 · ArgoNowta

About this eBook

In this book you will learn all the basics of psychedelics and why all this research is great news for public health in this century. After a very long and strange journey, psychedelics may finally be back for good.
Rick Doblin, PhD, Founder & Executive Director, MAPS.

In this guide you will learn all the essentials about the history, neuroscience, legality, therapeutic applications and harm reduction of the most promising psychedelic drugs for science. After decades of international prohibition these molecules are returning to laboratories and clinics, hand in hand with the most rigorous science, to revolutionize the way we understand and treat mental health (depression, anxiety, PTSD and addictions).

Discover the world of psilocybin, MDMA, DMT, ketamine and LSD, before society immerses in this revolution, which will forever change the perception we have of psychedelics.

This guide will be of interest to both therapists and other mental health professionals interested in the clinical applications, parents and educators seeking to understand the impact and safety of psychedelics and other drugs, as well as any adult curious to learn about and explore this new world of the psychedelic renaissance.

About the author

Psychopharmacologist and scientific analyst specialized in psychedelics, nootropics and other psychoactive drugs. Master on Psychopharmacology and Illicit Drugs at Madrid Complutense University. Works as a scientific advisor, researcher, international presenter, columnist at "Hemp Magazine", and with information, harm reduction, drug checking and psychedelic emergency tripsitting NGOs & programs, like Energy Control (ABD). Co-founder of Madrid's Psychedelic Society, he is member of the European psychedelic science association MIND and the Commission on International Drug Policy of the UNAD network and was a trainee at the European Monitoring Centre for Drugs and Drug Addiction EMCDDA of the EU.